scholarly journals Screening of potential diagnostic markers and therapeutic targets against colorectal cancer

2015 ◽  
pp. 1691 ◽  
Author(s):  
Jing Yuan Fang ◽  
XiaoQing Tian ◽  
DanFeng Sun ◽  
ShuLiang Zhao ◽  
Hua Xiong
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Targets ◽  
Diagnostic Markers

Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer

Surgery Today ◽  
2011 ◽  
Vol 41 (2) ◽  
pp. 175-182 ◽  
Author(s):  
Koh Miura ◽  
Wataru Fujibuchi ◽  
Kazuyuki Ishida ◽  
Takeshi Naitoh ◽  
Hitoshi Ogawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Targets ◽  
Diagnostic Markers ◽  
Protein Family ◽  
Inhibitor Of Apoptosis ◽  
Inhibitor Of Apoptosis Protein ◽  
Apoptosis Protein

scholarly journals Discovery of 830 candidate therapeutic targets and diagnostic markers for breast cancer using oligonucleotide microarray technology

10.1038/87236 ◽  
2001 ◽  
Vol 27 (S4) ◽  
pp. 77-77 ◽  
Author(s):  
Michael Orr ◽  
Amanda Williams ◽  
Lisa Vogt ◽  
Joseph Boland ◽  
Harry Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Therapeutic Targets ◽  
Diagnostic Markers ◽  
Oligonucleotide Microarray ◽  
Microarray Technology

scholarly journals Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 983 ◽  
Author(s):  
Otília Menyhart ◽  
Tatsuhiko Kakisaka ◽  
Lőrinc Sándor Pongor ◽  
Hiroyuki Uetake ◽  
Ajay Goel ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Gene Expression Data ◽  
Drug Targets ◽  
Therapeutic Targets ◽  
Independent Set ◽  
Driver Mutations ◽  
Expression Data ◽  
Expression Levels ◽  
Mutational Status

Background: Numerous driver mutations have been identified in colorectal cancer (CRC), but their relevance to the development of targeted therapies remains elusive. The secondary effects of pathogenic driver mutations on downstream signaling pathways offer a potential approach for the identification of therapeutic targets. We aimed to identify differentially expressed genes as potential drug targets linked to driver mutations. Methods: Somatic mutations and the gene expression data of 582 CRC patients were utilized, incorporating the mutational status of 39,916 and the expression levels of 20,500 genes. To uncover candidate targets, the expression levels of various genes in wild-type and mutant cases for the most frequent disruptive mutations were compared with a Mann–Whitney test. A survival analysis was performed in 2100 patients with transcriptomic gene expression data. Up-regulated genes associated with worse survival were filtered for potentially actionable targets. The most significant hits were validated in an independent set of 171 CRC patients. Results: Altogether, 426 disruptive mutation-associated upregulated genes were identified. Among these, 95 were linked to worse recurrence-free survival (RFS). Based on the druggability filter, 37 potentially actionable targets were revealed. We selected seven genes and validated their expression in 171 patient specimens. The best independently validated combinations were DUSP4 (p = 2.6 × 10−12) in ACVR2A mutated (7.7%) patients; BMP4 (p = 1.6 × 10−04) in SOX9 mutated (8.1%) patients; TRIB2 (p = 1.35 × 10−14) in ACVR2A mutated patients; VSIG4 (p = 2.6 × 10−05) in ANK3 mutated (7.6%) patients, and DUSP4 (p = 7.1 × 10−04) in AMER1 mutated (8.2%) patients. Conclusions: The results uncovered potentially druggable genes in colorectal cancer. The identified mutations could enable future patient stratification for targeted therapy.

scholarly journals Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD

2019 ◽  
Vol 105 (3) ◽  
pp. e390-e400 ◽  
Author(s):  
Stergios A Polyzos ◽  
Nikolaos Perakakis ◽  
Chrysoula Boutari ◽  
Jannis Kountouras ◽  
Wael Ghaly ◽  
...  
Keyword(s):  
Gene Expression ◽  
Liver Fibrosis ◽  
Therapeutic Targets ◽  
Diagnostic Markers ◽  
Oral Glucose ◽  
Simple Steatosis ◽  
Early Stages ◽  
Liver Gene ◽  
Circulating Levels ◽  
Igfbp 3

Abstract Aims To investigate circulating levels and liver gene expression of 3 hormonal pathways associated with obesity, insulin resistance, and inflammation to identify leads towards potential diagnostic markers and therapeutic targets in patients with nonalcoholic fatty liver disease (NAFLD). Methods We compared circulating levels of (1) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), (2) follistatins-activins (follistatin-like [FSTL]3, activin B), (3) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy-associated plasma protein [PAPP]-A) in 2 studies: (1) 18 individuals with early stage NAFLD versus 14 controls (study 1; early NAFLD study) and in (2) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs 50 controls (24 lean and 26 obese) (study 2). Liver gene expression was assessed in 22 subjects (12 controls, 5 NASH, 5 NASH-related cirrhosis). Results Patients in early stages of NAFLD demonstrate higher fasting MPGF and lower incremental increase of glicentin during oral glucose tolerance test than controls. In more advanced stages, FSTL3 levels are higher in NASH than simple steatosis and, within NAFLD patients, in those with more severe lobular and portal inflammation. The IGF-1/intact IGFBP-3 ratio is lower in patients with liver fibrosis. Genes encoding follistatin, activin A, activin B, and the IGF-1 receptor are higher in NASH. Conclusion MPGF and glicentin may be involved in early stages of NAFLD, whereas FSTL3 and IGF-1/intact IGFBP3 in the progression to NASH and liver fibrosis respectively, suggesting potential as diagnostic markers or therapeutic targets.

scholarly journals MiR-429 Involves in the Pathogenesis of Colorectal Cancer via Directly Targeting LATS2

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Xia Chen ◽  
Ai-li Wang ◽  
Yuan-yuan Liu ◽  
Chen-xi Zhao ◽  
Xue Zhou ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Solid Tumors ◽  
Therapeutic Targets ◽  
Multiple Cancer ◽  
Upstream Regulator ◽  
The World ◽  
Cancer Types ◽  
Metastasis Rate ◽  
Direct Regulator

Colorectal cancer (CRC) is a leading cause of cancer-related death around the world whose recurrence and metastasis rate is high. Due to the underlying unclear pathogenesis, it is hard so far to predict the tumorigenesis and prevent its recurrence. YAP/TAZ has been reported to be activated and functioned as a potential oncogene in multiple cancer types and proved to be essential for the carcinogenesis of most solid tumors. In the present study, we found that YAP/TAZ was markedly upregulated in CRC tissues comparing with the adjacent noncancerous tissues due to the downregulation of LATS2, the main upstream regulator. We further identified miR-429 as a direct regulator of LATS2-YAP/TAZ activation, suggesting that the miR-429-LATS2-YAP/TAZ might be novel effective diagnostic axis and therapeutic targets for CRC.

scholarly journals Potential Therapeutic Targets of B7 Family in Colorectal Cancer

2020 ◽  
Vol 11 ◽  
Author(s):  
Changgang Wang ◽  
Haoran Feng ◽  
Xi Cheng ◽  
Kun Liu ◽  
Dongli Cai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Targets ◽  
B7 Family

scholarly journals Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer

2016 ◽  
Vol 25 (3) ◽  
pp. 190-199 ◽  
Author(s):  
Sean M. Ronnekleiv-Kelly ◽  
Richard A. Burkhart ◽  
Timothy M. Pawlik
Keyword(s):  
Colorectal Cancer ◽  
Molecular Markers ◽  
Metastatic Colorectal Cancer ◽  
Therapeutic Targets
Sign in / Sign up

Export Citation Format

Share Document